• Raymund R Razonable, John C O'Horo, Douglas W Challener, Lori Arndt, Richard F Arndt, Caroline G Clune, Tracy L Culbertson, Scott T Hall, Alexander Heyliger, Tammy A Jackson, Brian D Kennedy, Jennifer Larsen, Sara N Hanson, Perry W Sweeten, Sidna M Tulledge-Scheitel, and Ravindra Ganesh.
• Mayo Clinic, Rochester, MN, USA; Mayo Clinic Health System, Eau Claire, WI, USA; Mayo Clinic Health System, Franciscan Skemp Healthcare, La Crosse, WI, USA; Mayo Clinic Health System, Mankato, MN, USA; Mayo Clinic Health System, Lake City, MN, USA. Electronic address: Razonable.raymund@mayo.edu.
• Mayo Clin. Proc. 2022 Sep 1; 97 (9): 1641-1648.

ObjectiveTo describe and compare the clinical outcomes of bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab treatment of mild to moderate coronavirus disease 2019 (COVID-19) during the severe acute respiratory coronavirus 2 (SARS-CoV-2) B.1.617.2 Delta surge.MethodsThis is a retrospective study of high-risk patients who received bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab for mild to moderate COVID-19 between August 1, 2021, and December 1, 2021. Rates of severe disease, hospitalization, intensive care unit admission, and death were assessed.ResultsAmong 10,775 high-risk patients who received bamlanivimab-etesevimab, casirivimab-imdevimab, or sotrovimab for mild to moderate COVID-19 during the Delta surge, 287 patients (2.7%) developed severe disease that led to hospitalization, oxygen supplementation, or death within 30 days after treatment. The rates of severe disease were low among patients treated with bamlanivimab-etesevimab (1.2%), casirivimab-imdevimab (2.9%), and sotrovimab (1.6%; P<.01). The higher rate of severe outcomes among patients treated with casirivimab-imdevimab may be related to a significantly lower COVID-19 vaccination rate in that cohort. Intensive care unit admission was comparable among patients treated bamlanivimab-etesevimab, casirivimab-imdevimab, or sotrovimab (1.0%, 1.0%, and 0.4%, respectively).ConclusionThis real-world study of a large cohort of high-risk patients shows low rates of severe disease, hospitalization, intensive care unit admission, and mortality after treatment with bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab for mild to moderate COVID-19 during the SARS-CoV-2 Delta surge.Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

27 keywords...

hide…